


Granted IN448419

Benzamide based hdac3 selective inhibitors



NEED

This invention aims to provide chemical compounds and pharmaceutical compositions for selective inhibition of histone deacetylase (HDAC) enzymes

SOLUTION

The invention provides compounds and pharmaceutical compositions, including those selectively inhibiting HDAC enzymes.

INNOVATION

The invention introduces compounds and pharmaceutical compositions with specific structures targeting HDAC enzymes, potentially advancing treatments for various diseases and disorders.

MARKET ANALYSIS

Market: Healthcare/Pharmaceutical Industry
CAGR: approximately 6-7%.

Potential Indian Clients: Pharmaceutical companies involved in drug discovery and development, such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Cadila Healthcare Ltd., and Biocon Ltd.

WHY INVEST?

- Selective inhibitors
- Epigenetic modifications
- Genetic expression
- Cancer treatment



AT A GLANCE

- Current TRL NA
- Funded by NA
- IPC A61K, C07D
- Domain
Pharmaceuticals/Drug Discovery

For more information, reach out to (contact person), (designation), (organization) at (email ID) and (phone number)



Prof. Ghosh Balaram, Prof. Biswas Swati,
Prof. Routholla Ganesh, Prof. Pulya
Sravani

Department of, Pharmacy
BITS Pilani, Hyderabad Campus

